Roche Reaffirms 2026 Outlook Despite Weak Vabysmo Sales, Strong Swiss Franc
Basel: Swiss drugmaker Roche confirmed its 2026 outlook on Thursday after first-half sales fell slightly in Swiss franc terms, dragged down by a stronger domestic currency and weaker-than-expected U.S. sales of its blockbuster eye drug Vabysmo.
Investors are focused on the second half of the year, when Roche is expected to expand launches of breast cancer drug Itovebi and other recently approved medicines. Roche is preparing for its next major commercial launch - giredestrant for breast cancer in the U.S. by the end of the year - and will also report data for one of its experimental obesity drugs.
Group sales for the first half were down 2% year-on-year at 30.36 billion Swiss francs ($37.34 billion), in line with analyst expectations of some 30.31 billion francs.
Sales rose 6% at constant exchange rates
Operating profit rose 10% at constant exchange rates to 11.86 billion Swiss francs, beating analyst expectations, but fell 1% in local currency terms due to Swiss franc appreciation.
Chief Executive Thomas Schinecker: "Should be a zero effect in terms of currencies in the second half of the year."
Roche confirmed outlook for growth in adjusted earnings per share in a high-single-digit range and sales growth in a mid-single-digit percentage range.
Schinecker said in an interview Roche expects most future deal opportunities to come from the U.S. and China.
Basel-based company's top-selling drugs - multiple sclerosis drug Ocrevus and haemophilia shot Hemlibra - grew 7% and 11% respectively from the same period last year.
Sales of blockbuster eye drug Vabysmo missed analyst expectations on weaker U.S. demand, competition.
China pricing reforms hit prices for diagnostic products, leading Roche's diagnostic sales there to fall 24%. The company said the impact should ease later in the year.
Also Read:Roche Strikes USD 2.3 Billion Nurix Deal for Blood Cancer Drug Bexobrutideg
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.